Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reaction
Adverse responses to rosiglitazone in type 2 diabetes model can be predicted by genetics
September 20th, 2006
Adverse hepatic and cardiac responses to rosiglitazone in type 2 diabetes model can be predicted by genetics. "Given the heterogeneous nature of metabolic dysfunctions associated with insulin resistance and type 2 diabetes (T2D), a single pharmaceutical cannot be expected to provide complication-free therapy in all patients. Thiazolidinediones (TZD) increase insulin sensitivity, reduce blood glucose and improve cardiovascular parameters. However, in addition to increasing fat mass, TZD have the potential in certain individuals to exacerbate underlying hepatosteatosis and diabetic cardiomyopathy. Pharmacogenctics should allow patient selection to maximize therapy and...
Source: Biotech Week (2006-09-20)
|
